Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

A Genome-Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium

(2013) Weihong Tang et al.   GENETIC EPIDEMIOLOGY

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE Study

(2013) Timothy L. Ramsey et al.   SCHIZOPHRENIA RESEARCH

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

(2012) R. M. Baldwin et al.   CLINICAL CANCER RESEARCH

Achieving the Best of Both Worlds

(2012) Andrew H. Ko et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

(2012) Bryan P Schneider et al.   LANCET ONCOLOGY

A genetic basis for the variable effect of smoking/nicotine on Parkinson’s disease

(2012) E M Hill-Burns et al.   PHARMACOGENOMICS JOURNAL

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Guidelines for Genome-Wide Association Studies

(2012) Gregory S. Barsh et al.   PLoS Genetics

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

(2011) Jenny J. Kim et al.   CANCER

Anti–Vascular Endothelial Growth Factor Therapy for Breast Cancer: Can We Pick the Winners?

(2011) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

(2010) Lokesh Jain et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY